The O O O O
goal O O O O
of O O O O
this O O O O
clinical O O O O
trial O O O O
is O O O O
to O O O O
test O O O O
the O O O O
safety, O O O O
tolerability, O O O O
and O O O O
efficacy O O O O
of O O O O
TG01 Reason 4 O O
vaccination Reason 4 O O
in Reason 4 O O
patients Reason 4 O O
with Reason 4 O O
KRAS Reason 4 O O
or Reason 4 O O
NRAS Reason 4 O O
mutation Reason 4 O O
on Reason 4 O O
codon Reason 4 O O
12/13 Reason 4 O O
mutation Reason 4 O O
who Reason 4 O O
has Reason 4 O O
multiple Reason 4 O O
myeloma Reason 4 O O
or Reason 4 O O
high-risk Reason 4 O O
smoldering Reason 4 O O
multiple Reason 4 O O
myeloma. Reason 4 O O
The O O O O
main O O O O
question O O O O
it O O O O
aims O O O O
to O O O O
answer O O O O
are: O O O O
Is Reason 3 O O
TG01/QS-21 Reason 3 O O
vaccination Reason 3 O O
safe Reason 3 O O
and Reason 3 O O
tolerable Reason 3 O O
for Reason 3 O O
this Reason 3 O O
patient Reason 3 O O
group? Reason 3 O O
Is Reason 3 O O
TG01/QS-21 Reason 3 O O
vaccination Reason 3 O O
treatment Reason 3 O O
efficient Reason 3 O O
in Reason 3 O O
this Reason 3 O O
group Reason 3 O O
in Reason 3 O O
terms Reason 3 O O
of Reason 3 O O
increased Reason 3 O O
overall Reason 3 O O
response Reason 3 O O
rate, Reason 3 O O
overall Reason 3 O O
survival Reason 3 O O
rate, Reason 3 O O
progression-free Reason 3 O O
survival, Reason 3 O O
and Reason 3 O O
time Reason 3 O O
til Reason 3 O O
next Reason 3 O O
treatment? Reason 3 O O
Is Reason 3 O O
there Reason 3 O O
an Reason 3 O O
immunological Reason 3 O O
response Reason 3 O O
to Reason 3 O O
the Reason 3 O O
vaccine? Reason 3 O O
Participants O O O O
will O O O O
be O O O O
given O O O O
TG01/QS-21 O O O O
vaccination O O O O
treatment. O O O O
Treatment O O O O
consists O O O O
of O O O O
12 O O O O
doses O O O O
of O O O O
TG01/QS-21 O O O O
vaccine O O O O
given O O O O
every O O O O
two O O O O
weeks O O O O
in O O O O
the O O O O
first O O O O
12 O O O O
weeks, O O O O
followed O O O O
by O O O O
every O O O O
eight O O O O
weeks O O O O
until O O O O
week O O O O
52 O O O O
